You are hereMay 29, 2019
Inherent cancer stem cell plasticity uncovered
LUXEMBOURG, May 2019 — Until now, researchers have assumed that the growth of solid tumors originates from cancer stem cells characterized by specific surface markers, which develop in a fixed, hierarchical order. Accordingly, such cancer stem cells are responsible for tumor progression and produce specific types of more differentiated cancer cells whose fates are predetermined.
In a joint interdisciplinary project led by the Luxembourg Institute of Health (LIH), researchers now show that cancer cells of glioblastomas — conspicuously aggressive solid brain tumors — manifest developmental plasticity and their phenotypic characteristics are less constrained than believed. Cancer stem cells, including their progeny, are able to adapt to environmental conditions and undergo reversible transformations into various cell types, thereby altering their surface structures. The results imply that novel therapeutic approaches, which target specific surface structures of cancer stem cells, will be of limited utility. The research team recently published its findings in Nature Communications.
Glioblastomas are the most common malignant brain tumors. Because of their rapid growth, the prognosis for those affected is usually dismal. Many patients hold out hope for novel therapeutic approaches, which utilize drug-bound antibodies directed against specific markers present on the surface of a subpopulation of immature glioblastoma cells. These antibody-drug conjugates bind to the surface, are then internalized and kill the cancer stem cells.
However, results suggest that this approach may be misdirected. “We exposed cancer cells in the laboratory to certain stressors, such as drug treatment or oxygen deficiency,” explained Anna Golebiewska, Ph.D., junior principal investigator at the NORLUX Neuro-Oncology Laboratory in LIH's Department of Oncology and co-first author of the study. “We were able to show that glioblastoma cells react flexibly to such stress factors and simply transform themselves at any time into cell types with a different set of surface markers.”
This plasticity allows the cells to adapt to their microenvironment and reach a favorable environment-specific heterogeneity that enables them to sustain and grow, and mostly likely to also escape therapeutic attacks.
The team of scientists from Luxembourg, Norway and Germany, led by Simone P. Niclou, Ph.D., at LIH, proposes that neoplastic cells of other tumor types may be also less constrained by defined hierarchical principles, but rather can adapt their characteristics to the prevailing environmental conditions. “The same phenomenon has been observed in breast and skin cancer,” said Dr. Golebiewska. “This observation predicts that cancer therapies specifically directed against cancer stem cell markers may not be successful in patients.”
The new findings could help to optimize future standard treatments. In laboratory experiments, the researchers were able to show that environmental factors, such as lack of oxygen, in combination with signals from the tumor microenvironment can induce cancer cells to modify their characteristics. This microenvironment, the immediate surrounding of the cancer, comprises cells and molecules that influence the growth of the tumor.
“Once we understand exactly what causes the plasticity of tumor cells, we can devise combination therapies which target the signals underlying plasticity and thereby improve the therapeutic impact,” Dr. Golebiewska said.